Johnson & Johnson vaccine vials.
The United States on Saturday February 27 granted emergency authorization for Johnson & Johnson’s vaccine against Covid-19 for people aged 18 and over, the United States Medicines Agency (FDA) announced. This single-dose vaccine called Janssen Covid-19, which can be stored at refrigerator temperatures, joins those of Pfizer / BioNTech and Moderna in the huge vaccination campaign in the United States, where the pandemic has killed more than 500,000 .
Article reserved for our subscribers Read also Covid-19: in the United States, the improvement of the situation clouded by the crossing of the threshold of 500,000 deaths
After studying in detail the data of clinical trials, conducted on more than 43,000 people, a committee of experts had recommended Friday the marketing of the vaccine of the American company.
At least three million doses of the “J&J” product are ready for distribution as early as next week, according to the US government. Johnson & Johnson has committed to ship 100 million doses to the United States by the end of June.
A “viral vector” vaccine
With 600 million doses ordered in total from Pfizer and Moderna, the United States will already have, by the end of July, enough vaccines to immunize almost the entire population. But the addition of those from Johnson & Johnson could further accelerate the vaccination campaign. In total, more than 72 million bites have already been carried out in the country most bereaved by the pandemic in absolute value.
Article reserved for our subscribers Read also Covid-19: how the fight against variants could modify vaccine strategies
The “J&J” vaccine, which injections have already started in South Africa, is a “viral vector” vaccine. It uses as a carrier another low virulent virus, transformed to add genetic instructions from part of the virus responsible for Covid-19. Once in the cells, a typical SARS-CoV-2 protein is produced, educating the immune system to recognize it.
“After rigorous analysis of the data, scientists and doctors at the FDA determined that the vaccine meets the FDA criteria for safety and efficacy for emergency authorization.”, the director of the agency’s biological assessment and research center, Peter Marks, said in a statement.
In clinical trials, the vaccine’s efficacy was 85.9% against severe forms of Covid-19 in the United States, according to figures released by the FDA. All regions of the clinical trial combined, it was 66.1% against moderate forms of the disease, and overall “Similar” for all categories of the population (ages, ethnic groups).
The most frequently observed side effects were pain at the injection site, headache, fatigue, and muscle pain.
Article reserved for our subscribers Read also Covid-19: the G7 commits to accelerate the deployment of vaccines in poor countries
I hope you are in health and well.
I offer you important instructions regarding this article
- The article has been translated based on the content of the source link below these instructions
If there is any problem related to the content, copyright, correctness of the information contained in this article, or If there are errors in the language, please leave a report below the article. or contact us via email [email protected]. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
- We only want readers to access information quickly and easily using other multilingual content, rather than information only available in a specific language.
- We always respect the copyright of the author’s content and always include the original link of the source article, and if the author does not agree, leave the report below the article, the article will be edited or deleted at the author’s request. Thank you so much! Warm greetings!